Beigene, Ltd. (NASDAQ:ONC) Insider Sells $10,911,052.80 in Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $261.28, for a total value of $10,911,052.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The shares were sold at an average price of $254.58, for a total value of $2,073,808.68.

Beigene Stock Down 4.0 %

NASDAQ:ONC opened at $251.98 on Friday. Beigene, Ltd. has a twelve month low of $126.97 and a twelve month high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company has a market cap of $24.79 billion, a price-to-earnings ratio of -30.58, a PEG ratio of 7.73 and a beta of 0.65.

Beigene (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. On average, research analysts expect that Beigene, Ltd. will post -5.82 EPS for the current year.

Analyst Ratings Changes

ONC has been the subject of several research analyst reports. Sanford C. Bernstein set a $259.00 price objective on Beigene in a research report on Thursday, March 13th. Guggenheim reaffirmed a “buy” rating on shares of Beigene in a research report on Friday, February 28th. JMP Securities set a $348.00 price target on Beigene in a research report on Friday, February 28th. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and upped their price target for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Finally, Macquarie upped their price target on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.